Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Saved in:
Bibliographic Details
Main Authors: Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-10-01
Series:Dermatology and Therapy
Online Access:https://doi.org/10.1007/s13555-024-01269-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846165581947994112
author Jonathan I. Silverberg
Andreas Wollenberg
Linda Stein Gold
James Del Rosso
Gil Yosipovitch
Peter Lio
Jose-Manuel Carrascosa
Gaia Gallo
Yuxin Ding
Zhenhui Xu
Marta Casillas
Evangeline Pierce
Helena Agell
Sonja Ständer
author_facet Jonathan I. Silverberg
Andreas Wollenberg
Linda Stein Gold
James Del Rosso
Gil Yosipovitch
Peter Lio
Jose-Manuel Carrascosa
Gaia Gallo
Yuxin Ding
Zhenhui Xu
Marta Casillas
Evangeline Pierce
Helena Agell
Sonja Ständer
author_sort Jonathan I. Silverberg
collection DOAJ
format Article
id doaj-art-d06ef00c21c84ee48845e758fed856a9
institution Kabale University
issn 2193-8210
2190-9172
language English
publishDate 2024-10-01
publisher Adis, Springer Healthcare
record_format Article
series Dermatology and Therapy
spelling doaj-art-d06ef00c21c84ee48845e758fed856a92024-11-17T12:10:33ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722024-10-0114113195319610.1007/s13555-024-01269-yPublisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab TreatmentJonathan I. Silverberg0Andreas Wollenberg1Linda Stein Gold2James Del Rosso3Gil Yosipovitch4Peter Lio5Jose-Manuel Carrascosa6Gaia Gallo7Yuxin Ding8Zhenhui Xu9Marta Casillas10Evangeline Pierce11Helena Agell12Sonja Ständer13George Washington University School of MedicineDepartment of Dermatology and Allergy, University Hospital AugsburgHenry Ford Health SystemJDR Dermatology ResearchMiller School of Medicine, University of MiamiNorthwestern University Feinberg School of MedicineHospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTPEli Lilly and CompanyEli Lilly and CompanyCIMS Global LLCEli Lilly and CompanyEli Lilly and CompanyAlmirall S.A.Center for Chronic Pruritus and Department of Dermatology, University Hospital Münsterhttps://doi.org/10.1007/s13555-024-01269-y
spellingShingle Jonathan I. Silverberg
Andreas Wollenberg
Linda Stein Gold
James Del Rosso
Gil Yosipovitch
Peter Lio
Jose-Manuel Carrascosa
Gaia Gallo
Yuxin Ding
Zhenhui Xu
Marta Casillas
Evangeline Pierce
Helena Agell
Sonja Ständer
Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
Dermatology and Therapy
title Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
title_full Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
title_fullStr Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
title_full_unstemmed Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
title_short Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
title_sort publisher correction patients with moderate to severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of lebrikizumab treatment
url https://doi.org/10.1007/s13555-024-01269-y
work_keys_str_mv AT jonathanisilverberg publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT andreaswollenberg publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT lindasteingold publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT jamesdelrosso publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT gilyosipovitch publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT peterlio publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT josemanuelcarrascosa publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT gaiagallo publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT yuxinding publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT zhenhuixu publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT martacasillas publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT evangelinepierce publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT helenaagell publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment
AT sonjastander publishercorrectionpatientswithmoderatetosevereatopicdermatitismaintainstableresponsewithnoorminimalfluctuationswith1yearoflebrikizumabtreatment